Modified antibody fragments
View Patent ↗The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) and light (CL) chain constant regions is absent and the heavy chain (CHI) and light chain (CL) constant regions are linked by an interchain disulphide bond between a pair of engineered cysteines, one in the light chain constant (CL) region and the other in the heavy chain constant (CHI) region.
1. An antibody fragment having a heavy chain constant region (C H 1) and a light chain constant region (C L ), one or more effector molecules being attached to said fragment, said fragment characterized in that the native interchain disulphide bond between native interchain cysteines in the heavy (C H 1) and light (C L ) chain constant regions is absent and the heavy chain (C H 1) and light chain (C L ) constant regions are linked by an interehain disulphide bond between a pair of engineered cysteines, one in the light chain constant (C L )region and the other in the heavy chain constant (C H 1) region, wherein the position of the pair of engineered cysteines is selected form position 116 of the light chain and 138 of the heavy chain, position 119 of the light chain and 128 of the heavy chain or position 210 of the light chain and 129 of the heavy chain, said positions as defined by the Kabat numbering system for IgG1.
2. An antibody fragment according to claim 1 in which at least one effector molecule is attached to a cysteine in the antibody fragment.
3. An antibody fragment having a heavy chain constant region (C H 1) and a light chain constant region (C L ), said fragment characterized in that the native interchain disulphide bond between native interchain cysteines in the heavy (C H 1) and light (C L ) chain constant regions is absent, in which the heavy chain (C H 1) and light chain (C L )constant regions are linked by an interchain disulphide bond between a pair of engineered cysteines characterized in that the position of the pair of cysteines is selected from position 116 of the light chain and 138 of the heavy chain, position 119 of the light chain and 128 of the heavy chain or position 210 of the light chain and 129 of the heavy chain, said positions as defined by the Kabat numbering system for IgG1.
4. The antibody fragment according to claim 1 in which the antibody fragment is a Fab or Fab′.
5. The antibody fragment according to claim 1 wherein the native interchain cysteines have been replaced by another amino acid.
6. The antibody fragment according to claim 5 in which the native interchain cysteines have been replaced by serine.
7. The antibody fragment according to claim 1 in which the antibody fragment is a Fab′ and an effector molecule is attached to a cysteine in the hinge region.
8. The antibody fragment according to claim 1 in which an effector molecule is attached to each of the interchain cysteines.
9. The antibody fragment according to claim 1 in which the effector molecule is PEG.
10. The antibody fragment according to claim 3 in which the antibody fragment is a Fab or Fab′.
11. The antibody fragment according to claim 3 wherein the native interchain cysteines have been replaced by another amino acid.
12. The antibody fragment according to claim 11 in which the native interchain cysteines have been replaced by serine.